Liubao Peng

Liubao Peng

Auto-generated profile, based on publicly available information

Liubao Peng

Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2019 in Cancer
Verified
Journal Article
Closed access
PDF file
XWXiaoMin Wan
XiaoMin Wan
XLXia Luo
Xia Luo
CTChongqing Tan
Chongqing Tan
XZXiaoHui Zeng
XiaoHui Zeng
YZYuCong Zhang
YuCong Zhang
LPLiuBao Peng
LiuBao Peng

1 February 2019 in The Breast
Verified
Journal Article
Closed access
XWXiaoMin Wan
XiaoMin Wan
YZYuCong Zhang
YuCong Zhang
JMJinAn Ma
JinAn Ma
CTChongqing Tan
Chongqing Tan
XZXiaoHui Zeng
XiaoHui Zeng
LPLiuBao Peng
LiuBao Peng

1 October 2019 in Advances in Therapy
Verified
Journal Article
Closed access
PDF file
YPYe Peng
Ye Peng
FMFang Ma
Fang Ma
CTChongqing Tan
Chongqing Tan
XWXiaomin Wan
Xiaomin Wan
LYLidan Yi
Lidan Yi
XZXiaohui Zeng
Xiaohui Zeng

10 November 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
CPCiyan Peng
Ciyan Peng
JCJing Chen
Jing Chen
WCWei Cui
Wei Cui
SLSini Li
Sini Li
JLJianhe Li
Jianhe Li
LPLiubao Peng
Liubao Peng
Background: Given the limitations of Western medicine (WM) for the treatment of non-small cell lung cancer (NSCLC) and the wide exploration of Chinese herbal injections (CHIs), systematically evaluate the efficacy of Various CHIs Combined with WM for Non-small Cell Lung Cancer. In this study, we performed a network meta-analysis to evaluate the comparative efficacy of 16 CHIs combined with WM regimens for the treatment of NSCLC.Methods: Literature databases were searched from their inception to November 2021, and all randomized control trials (RCTs) involving NSCLC patients treated with a combination of Chinese and WM were retrieved. Outcomes, including disease control rate, survival quality score, incidence of gastrointestinal adverse reactions, incidence of leukopenia, and incidence of thrombocytopenia, were analyzed using RevMan (5.3), Stata17, and R software. Surface under the cumulative ranking curve (SUCRA) probability values were calculated to rank the treatments examined, and clustering analysis was used to compare the effects of CHIs on different outcomes.Results: A total of 389 studies involving 31,263 patients and 16 CHIs were included. The 16 CHIs were: Aidi injection (ADI), Huachansu injection (HCSI), oil of Ophiopogon injection (OOMI), disodium cantharidinate and vitamin B6 injection (DCI), Shenfu injection (SFI), Shenmai injection (SMI), Shenqi Fuzheng injection (SQFZI), Chansu injection (CSI), Delisheng injection (DLSI), Fufang Kushen injection (FFKSI), Huangqi injection (HQI), Kangai injection (KAI), Kanglaite injection (KLTI), Shengmai injection (SI), Xiangguduotang injection (XGDTI), and Xiaoaiping injection (XAPI). The results of the network meta-analysis showed that, with WM treatment as a co-intervention, CSI was most likely to improve the disease control rate (SUCRA = 80.90%), HQI had the highest probability of being the best option for improving the survival quality score (SUCRA = 82.60%), DCI had the highest probability of reducing the incidence of gastrointestinal adverse reactions (SUCRA = 85.50%), HCSI + WM had the highest probability of reducing the incidence of thrombocytopenia (SUCRA = 91.30%), while SMI had the highest probability of reducing the incidence of leukopenia (SUCRA = 79.10%).Conclusion: CHIs combined with WM is proved to be more effective than WM alone, which may be beneficial to NSCLC patients. SMI + WM and DCI + WM are most likely the optimal CHI to improve disease control rates, survival quality score, and reduce adverse effects. This study has limitations; therefore, higher quality RCTs and real-world evidence are required to support our conclusions.